IL1B and periodic fever syndrome: The chosen IL-1β inhibitor, canakinumab, had been used since its FDA approval in 2009 for the treatment of the rare inherited disorder cryopyrin-associated periodic syndromes (CAPS), in which IL-1β is over-secreted, as well as for the treatment of other inflammatory conditions such as gout and periodic fever syndromes.